# Efficacy and Tolerability of a New Oral Extended-Release Formulation Containing Parnaparin Sodium, Administered Add-on Therapy

> **NCT00867438** · PHASE2 · COMPLETED · sponsor: **Cosmo Technologies Ltd** · enrollment: 133 (actual)

## Conditions studied

- Ulcerative Colitis

## Interventions

- **PROCEDURE:** Sigmoidoscopy

## Key facts

- **NCT ID:** NCT00867438
- **Lead sponsor:** Cosmo Technologies Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-01
- **Primary completion:** 2007-11
- **Final completion:** 2007-11
- **Target enrollment:** 133 (ACTUAL)
- **Last updated:** 2009-03-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00867438

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00867438, "Efficacy and Tolerability of a New Oral Extended-Release Formulation Containing Parnaparin Sodium, Administered Add-on Therapy". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00867438. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*